Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner

Cancer Research

Volumn 67, Issue 11, 2007, Pages 5498-5504

  Kobayashi, Hiroya ^a   Nagato, Toshihiro ^a   Sato, Keisuke ^a   Aoki, Naoko ^a   Kimura, Shoji ^a   Murakami, Masamoto ^a   Iizuka, Hajime ^a   Azumi, Makoto ^a   Kakizaki, Hidehiro ^a   Tateno, Masatoshi ^a   Celis, Esteban ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLLYSYLCYCLOHEXYLALANYLVALYLALANYLALANYLTRYPTOPHYL THREONYLLEUCYLLYSYLALANYLALANYLALANINE; CANCER VACCINE; EPITOPE; GLUTAMINYLALANYLARGINYLMETHIONYLPHENYLALANYLPROLYL ASPARAGINYLALANYLPROLYLTYROSYLLEUCYLPROLYLSERYLCYSTEINYLISOLEUCINE; HISTIDYLGLUTAMINYLGLUTAMINYLTYROSYLPHENYLALANYLTYROSYLLYSYL ISOLEUCYLPROLYLISOLEUCYLLEUCYLVALYLISOLEUCYLASPARAGINYLLYSINE; HLA ANTIGEN CLASS 2; LEUCYLLEUCYLASPARAGINYLTRYPTOPHYLALANYLTYROSYLGLUTAMINYL GLUTAMINYLVALYLGLUTAMINYLGLUTAMINYLASPARAGINYLLYSYLGLUTAMYLASPARTIC ACID; LEUCYLPROLYLGLYCYLVALYLISOLEUCYLALANYLALANYLISOLEUCYLVALYL GLUTAMINYLLEUCYLHISTIDYLASPARAGINYLGLYCYLTHREONINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VALYLVALYLLEUCYLISOLEUCYLPHENYLALANYLLYSYLSERYLISOLEUCYLLEUCYLPHENYL ALANYLLEUCYLPROLYLCYSTEINYLLEUCYLARGININE;

ALGORITHM; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELLULAR IMMUNITY; CONTROLLED STUDY; HELPER CELL; HLA SYSTEM; HUMAN; HUMAN CELL; MALE; MELANOMA; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DENDRITIC CELLS; EPITOPES; EPITOPES, T-LYMPHOCYTE; HLA-DR ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 34347210340     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0304     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999;96:14523-8.
3. Rodeberg DA, Nuss RA, Elsawa SF, Celis E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 2005;11:4545-52.
4. Machlenkin A, Paz A, Bar Haim E, et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005;65:6435-42.
5. + T cells. Cancer Immunol Immunother 2006;55:1515-23.
6. Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007;67:1344-51.
7. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999;190:617-27.
8. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001;22:269-76.
9. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4T cell help. Science 2003;300:339-42.
10. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
11. Mumberg D, Monach PA, Wanderling S, et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc Natl Acad Sci U S A 1999;96:8633-8.
12. Kennedy R, Celis E. T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol 2006;177:2862-72.
13. Giuntoli RL II, Lu J, Kobayashi H, Kennedy R, Celis E. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 2002;8:922-31.
14. Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998;160:3363-73.
15. Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 2000;60:5228-36.
16. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43.
17. Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 2001;61:7577-84.
18. Kobayashi H, Song Y, Hoon DS, Appella E, Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 2001;61:4773-8.
19. Kobayashi H, Omiya R, Ruiz M, et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002;8:3219-25.
20. Omiya R, Buteau C, Kobayashi H, Paya CV, Celis E. Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol 2002;169:2172-9.
21. Kobayashi H, Omiya R, Sodey B, et al. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation. Clin Cancer Res 2003;9:5386-93.
22. + helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein. Clin Cancer Res 2004;10:7053-62.
23. Kobayashi H, Nagato T, Oikawa K, et al. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin Cancer Res 2005;11:3869-78.
24. + helper T lymphocytes. Clin Cancer Res 2006;12:3814-22.
25. Kobayashi H, Nagato T, Aoki N, et al. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 2006;55:850-60.
26. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1:751-61.
27. Kawashima I, Hudson SJ, Tsai V, et al. The multiepitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998;59:1-14.
28. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002;62:5807-12.
29. Horiguchi Y, Nukaya I, Okazawa K, et al. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 2002;8:3885-92.
30. Schroers R, Shen L, Rollins L, et al. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res 2003;9:3260-71.
31. Carlsson B, Totterman TH, Essand M. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. Prostate 2004;61:161-70.
32. Oh S, Terabe M, Pendleton CD, et al. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004;64:2610-8.
33. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-40L interactions. Nature 1998;393:480-3.
34. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-80.
35. + T-helper and a T-killer cell. Nature 1998;393:474-8.
36. + T cells and shared among tumors of different histology. Clin Cancer Res 2006;12:4949-57.